Therefore, increased serum VEGF-D and ANG-2 levels might contribute to resistance to atezolizumab plus bevacizumab for unresectable HCC, and might be remarkable target molecules in subsequent salvage therapies. The gene discussed is VEGFD; the disease is hepatocellular carcinoma.